Literature DB >> 22850750

Targeted therapies: the toxic reality of new drugs.

Rebecca Kirk.   

Abstract

Year:  2012        PMID： 22850750     DOI： 10.1038/nrclinonc.2012.134

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs.

Authors:  Saroj Niraula; Bostjan Seruga; Alberto Ocana; Tiffany Shao; Robyn Goldstein; Ian F Tannock; Eitan Amir
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544
  1 in total
  4 in total

1.  Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles.

Authors:  Rong Xu; QuanQiu Wang
Journal:  J Biomed Inform       Date:  2015-03-27       Impact factor: 6.317

2.  Applications for oncologic drugs: a descriptive analysis of the oncologic drugs advisory committee reviews.

Authors:  John K Chan; Tuyen K Kiet; Bradley J Monk; Nichole Young-Lin; Kevin Blansit; Daniel S Kapp; Idoroenyi Amanam
Journal:  Oncologist       Date:  2014-03-05

3.  Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma.

Authors:  Tiziana Petrachi; Alessandra Romagnani; Adriana Albini; Caterina Longo; Giuseppe Argenziano; Giulia Grisendi; Massimo Dominici; Alessia Ciarrocchi; Katiuscia Dallaglio
Journal:  Oncotarget       Date:  2017-01-24

4.  Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy.

Authors:  Bryan Oronsky; Corey Carter; Anna Scicinska; Arnold Oronsky; Neil Oronsky; Michelle Lybeck; Jan Scicinski
Journal:  Oncotarget       Date:  2016-02-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.